Savara Inc.

Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases in the United States. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF), currently in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company aims to address unmet medical needs in rare lung conditions.

Savara Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SVRA. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States.

Savara Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on developing therapies for rare respiratory diseases, which falls under the broader biotechnology and pharmaceutical research and development category.

Savara Inc. is headquartered in Langhorne, Pennsylvania, United States. The company primarily serves the US market, as indicated by its focus on rare respiratory diseases within the country. Its operations are centered on clinical development and regulatory activities in the US.

Savara Inc.'s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF). It is currently in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease. The company is advancing this candidate through clinical trials to seek regulatory approval.